Remission of Schizophrenia Seen With Amisulpride, Clozapine

September 04, 2018

Overall, 45 and 44% on amisulpride and olanzapine, respectively, achieved remission (P=.87). Twenty-eight of the 40 patients not in remission started clozapine; 28% of the 18 patients who completed treatment achieved remission.

Peer Comparisons Can Decrease Risky Prescribing Patterns

August 14, 2018

Over 9 months, the treatment arm prescribed 11.1% fewer quetiapine days per prescriber vs the control arm (P<.001; adjusted difference, −319 days; P<.001), which persisted over 2 years (15.6% fewer days; P<.001).

Antipsychotic Tx Linked to Adiposity Changes in Youths

June 14, 2018

The researchers found that from baseline to week 12, the dual-energy X-ray absorptiometry percentage total body fat increased by 1.18, 4.12, and 1.66% for risperidone, olanzapine, and aripiprazole, respectively, and was significantly greater for olanzapine than risperidone or aripiprazole.

FDA Fast Tracks Drug for Hallucinations Disorder in Lewy Body Dementia

By June 19, 2017

Nelotanserin is a novel once-daily oral 5HT2A inverse agonist. The 5HT2A receptor has been associated with neuropsychiatric effects, including visual hallucinations.

Communication Training May Help Cut Nursing Home Antipsychotic Use

April 21, 2017

Researchers found that nursing homes enrolled in the OASIS program had a 7.6% drop in antipsychotic prescriptions, compared with a 3.9% decline at the other nursing homes.

First Physiological Biomarker Shows Promise in ID'ing Psych Disorders

March 15, 2017

The research team used hypertonic saline to induce the release of arginine-vasopressin, with each patient's blood then tested for arginine-vasopressin.

Sedating, Activating Effects of Second-Generation Antipsychotics Compared

By February 01, 2017

Second-generation antipsychotic agents, used for the treatment of schizophrenia and major depressive disorder (MDD), are associated with varying degrees of activating or sedating adverse effects (AEs), with some agents having both properties.

FDA to Review Abilify Maintena for Bipolar I Disorder

By November 30, 2016

Otsuka and Lundbeck announced that the Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for the expanded labeling of Abilify Maintena (aripiprazole extended-release) for the maintenance treatment of bipolar I disorder in adults.

Contraindication with Depression Med Prompts Labeling Update for Several HIV Drugs

By September 20, 2016

A batch of antiretroviral drug labels has been updated to include Contraindications with an antidepressant.

Antipsychotic Use in Alzheimer's Patients May Up Pneumonia Risk

By August 30, 2016

New research published in Chest indicates that use of antipsychotic medications may be associated with a higher risk of pneumonia in patients with Alzheimer's disease.

Treatment Adherence Evaluated in Patients with Schizoaffective Disorder

By August 25, 2016

A study in the Journal of Clinical Psychopharmacology found that overall use of long-acting injectable antipsychotics for the treatment of schizoaffective disorder was low, and adherence to antipsychotics was suboptimal among these patients in the real-world setting.

Expanded Dosing Interval for Aristada Under FDA Review

By August 08, 2016

Alkermes announced that it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a two-month dosing interval of Aristada (aripiprazole lauroxil), providing a third dosing option for the treatment of schizophrenia.

Examination of Patient Delusions in ICUs Reveal Fact & Fiction

August 02, 2016

Memories of delusions in the intensive care unit are composed of a mixture of fact and fiction, and are not dependent on the presence of delirium, according to a study published online July 26 in the Journal of Clinical Nursing.

Benefits, Safety of Paliperidone Injectable vs. ER Tablet Compared for Schizophrenia Maintenance

By July 21, 2016

An analysis published in International Clinical Psychopharmacology found that paliperidone palmitate once-monthly (PP1M) had a more favorable benefit-risk profile compared to oral paliperidone extended-release (ER) in the maintenance treatment of schizophrenia through Week 40.

Drug Combo May Improve Psychopathology, Lower BMI in Schizophrenia Patients

By July 18, 2016

Co-treatment with topiramate and an antipsychotic significantly decreased total, positive, negative, and general psychopathology and weight/body mass index (BMI) in patients with schizophrenia spectrum disorder while being well tolerated, a meta-analysis in the Journal of Clinical Psychology reported.